Third-day weight changes and bronchopulmonary dysplasia risk in preterm infants: a cohort study.

Front Pediatr

Department of Neonatology, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China.

Published: May 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: Fluid balance and weight changes in the early postnatal period are critical indicators of neonatal adaptation and have been implicated in the development of complications in preterm infants. However, the relationship between early weight changes and the risk of bronchopulmonary dysplasia (BPD) remains unclear. This study aimed to evaluate the association between weight change by the third day of life and the subsequent risk of BPD in preterm infants.

Study Design: A retrospective cohort study included preterm infants <32 weeks gestation or <1,500 g birth weight. Logistic regression was used to assess the association between weight change by day 3 (percentage change from birth weight) and BPD.

Results: Among 453 infants, 97.4% ( = 441) had weight changes between -15% and 5%, with a BPD incidence of 34.2%. Each 1% increase in weight change by day 3 was linked to a 10% increase in BPD risk (OR = 1.10, 95% CI: 1.03-1.18). Infants without weight loss had a 2.52-fold higher BPD risk (OR = 2.52, 95% CI: 1.34-4.80).

Conclusion: Weight loss byday 3 is associated with a lower BPD risk in preterm infants. The day 3 weight change is a noninvasive and simple early predictor of BPD, and optimizing early fluid management to guide appropriate weight changes may help reduce BPD incidence.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148873PMC
http://dx.doi.org/10.3389/fped.2025.1592069DOI Listing

Publication Analysis

Top Keywords

weight changes
12
preterm infants
12
bronchopulmonary dysplasia
8
cohort study
8
third-day weight
4
changes bronchopulmonary
4
dysplasia risk
4
preterm
4
risk preterm
4
infants cohort
4

Similar Publications

Introduction: This post hoc analysis of an A Toujeo Observational Study (ATOS) aims to evaluate the real-world effectiveness and safety of insulin glargine 300 U/ml (Gla-300) in high-risk subgroups of insulin-naïve people with type 2 diabetes (PwT2D) from multiple geographical regions (Asia, the Middle East, North Africa, Latin America, and Eastern Europe).

Methods: In these post hoc analyses of ATOS, a real-world, 12-month, prospective study included 4422 insulin-naïve adults (age ≥ 18 years) with type 2 diabetes (T2D) uncontrolled (HbA > 7% and ≤ 11%) on one or more oral antidiabetic drugs (OADs) who initiated Gla-300 treatment as per routine practice. Primary and secondary endpoints were studied according to renal impairment (RI) status (without or with) and age group ( View Article and Find Full Text PDF

Poly(γ-stearyl-l-glutamate) (PSLG) is a semiflexible synthetic polypeptide that forms both thermotropic and lyotropic liquid crystal (LC) phases. We previously showed that spherical nanoparticles (NPs) decorated with another semiflexible helical polymer, poly(hexyl isocyanate), form lyotropic nematic rather than cubic LC phases. In this work, PSLG ligands for functionalizing 4 nm ZrO NPs were prepared via N-carboxyanhydride ring-opening polymerization.

View Article and Find Full Text PDF

Introduction: Sulforaphane (SFN) is recognized for its anti-inflammatory properties; however, the underlying molecular mechanisms remain unclear. In this study, we explored the effect of SFN on subarachnoid hemorrhage (SAH) and the potential mechanisms.

Methods: Sprague-Dawley (SD) rats were divided into three groups (n = 12): Sham + vehicle group (Sham + V), SAH + vehicle group (SAH + V), and SAH + SFN group (SAH + S).

View Article and Find Full Text PDF

Background: Antipsychotics are associated with side effects like weight gain, obesity, and menstrual disorders in Women, which can reduce treatment compliance and increase cardiovascular, metabolic risks, dementia, and other chronic diseases, as well as increase mortality, and reduce the quality of life in patients. Data on these effects in Vietnam are limited. This study evaluated changes in body weight, BMI, menstrual cycle, and metabolic syndrome components among female schizophrenic inpatients treated with antipsychotics.

View Article and Find Full Text PDF